All In Biotech

Drug Trial Radar · NCT02174627

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis

Last checked: Nov 19, 2026Latest source record: Dec 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,781 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,781

Actual

Start

Jun 26, 2014

Primary completion

Oct 4, 2018

Study completion Oct 4, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Kyntra Bio
First posted
Jun 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis

Conditions

  • Anemia

Interventions

  • RoxadustatDrug

    The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.

  • PlaceboDrug

    The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52Time frame: Baseline (Day 1, Week 0) and Week 28 to Week 52.

Locations

359 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    El Centro, California

  • Research Site

    Escondido, California

  • Research Site

    Glendale, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Lynwood, California

  • Research Site

    National City, California

  • Research Site

    Northridge, California

  • Research Site

    Orange, California

  • Research Site

    Sacramento, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Dimas, California

  • Research Site

    San Francisco, California

  • Research Site

    San Luis Obispo, California

  • Research Site

    Upland, California

  • Research Site

    Arvada, Colorado

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Aventura, Florida

  • Research Site

    Coral Gables, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    Edgewater, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Lauderdale Lakes, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Port Charlotte, Florida

Showing 40 of 359 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.